![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WK Eng, FL McCabe, KB Tan, MR Mattern, GA Hofmann, RD Woessner, RP Hertzberg and RK Johnson
Department of Biomolecular Discovery, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
A camptothecin-resistant subline of P388 leukemia (P388/CPT) was developed by repeated transplantation of P388 cells in mice treated with therapeutic doses of camptothecin. In mice bearing the resistant tumor, a maximally tolerated dose of camptothecin produced no net reduction in tumor cell burden, in contrast to a 5-log cell kill in the parental P388 (P388/S). The IC50 of camptothecin, as determined by colony formation assays of cultured cells, was 8 times greater for the cloned P388/CPT cell line than for P388/S. P388/CPT cells were not cross-resistant to other antineoplastic agents, including topoisomerase II inhibitors. The type I topoisomerases purified from P388/CPT and P388/S cells were identical with respect to molecular weight, specific activity, in vitro camptothecin sensitivity, and DNA cleavage specificity. Camptothecin induced fewer protein-associated DNA single- strand breaks in the resistant cells than in the wild-type P388 cells. Topoisomerase I mRNA, immunoreactivity, and extractable enzymatic activity were 2-4 times lower for P388/CPT cells than for P388/S cells. As resistance to camptothecin developed, topoisomerase I extractable activity decreased, concomitant with an increase in topoisomerase II extractable activity. Furthermore, the appearance of camptothecin resistance was associated with specific rearrangements of the topoisomerase I gene. These results suggest that development of resistance to inhibitors of topoisomerase I can occur by down- regulation of the target enzyme, thus reducing the production of lethal enzyme-mediated DNA damage. The enhanced topoisomerase II activity in these cells suggests that resistance to camptothecin may be overcome by co-treatment with topoisomerase II inhibitors.
This article has been cited by other articles:
|
|
 |
|
  Z. Liao, R. W. Robey, J. Guirouilh-Barbat, K. K. W. To, O. Polgar, S. E. Bates, and Y. Pommier Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan Mol. Pharmacol., February 1, 2008; 73(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Simon, R. M. Lush, J. Gump, L. Tetteh, C. Williams, A. Cantor, S. Antonia, C. Garrett, C. Rocha-Lima, M. Fishman, et al. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol. Cancer Ther., August 1, 2006; 5(8): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Arakawa, H. Suzuki, S. Saito, and H. Yamada Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol. Cancer Ther., March 1, 2006; 5(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Marquis, I. Hardy, and M. Olivier Topoisomerase I Amino Acid Substitutions, Gly185Arg and Asp325Glu, Confer Camptothecin Resistance in Leishmania donovani Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1441 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Daroui, S. D. Desai, T.-K. Li, A. A. Liu, and L. F. Liu Hydrogen Peroxide Induces Topoisomerase I-mediated DNA Damage and Cell Death J. Biol. Chem., April 9, 2004; 279(15): 14587 - 14594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boyer, E. G. McLean, S. Aroori, P. Wilson, A. McCulla, P. D. Carey, D. B. Longley, and P. G. Johnston Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan Clin. Cancer Res., March 15, 2004; 10(6): 2158 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hu, A. Krishan, W. Nie, K. S. Sridhar, L. D. Mayer, and M. Bally Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells Clin. Cancer Res., February 1, 2004; 10(3): 1160 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aisner, R. Musanti, S. Beers, S. Smith, S. Locsin, and E. H. Rubin Sequencing Topotecan and Etoposide Plus Cisplatin to Overcome Topoisomerase I and II Resistance: A Pharmacodynamically Based Phase I Trial Clin. Cancer Res., July 1, 2003; 9(7): 2504 - 2509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Park, W. Lam, and Y.-c. Cheng X-ray Repair Cross-Complementing Gene I Protein Plays an Important Role in Camptothecin Resistance Cancer Res., January 1, 2002; 62(2): 459 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Gamcsik, M. S. Kasibhatla, D. J. Adams, J. L. Flowers, O. M. Colvin, G. Manikumar, M. Wani, M. E. Wall, G. Kohlhagen, and Y. Pommier Dual Role of Glutathione in Modulating Camptothecin Activity: Depletion Potentiates Activity, but Conjugation Enhances the Stability of the Topoisomerase I-DNA Cleavage Complex Mol. Cancer Ther., November 1, 2001; 1(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maliepaard, M. A. van Gastelen, A. Tohgo, F. H. Hausheer, R. C. A. M. van Waardenburg, L. A. de Jong, D. Pluim, J. H. Beijnen, and J. H. M. Schellens Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918 Clin. Cancer Res., April 1, 2001; 7(4): 935 - 941. [Abstract] [Full Text]
|
|
|
|
 |
|
 U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Urasaki, G. S. Laco, P. Pourquier, Y. Takebayashi, G. Kohlhagen, C. Gioffre, H. Zhang, D. Chatterjee, P. Pantazis, and Y. Pommier Characterization of a Novel Topoisomerase I Mutation from a Camptothecin-resistant Human Prostate Cancer Cell Line Cancer Res., March 1, 2001; 61(5): 1964 - 1969. [Abstract] [Full Text]
|
|
|
|
|
|
H. Komatani, M. Morita, N. Sakaizumi, K. Fukasawa, E. Yoshida, A. Okura, T. Yoshinari, and S. Nishimura A New Mechanism of Acquisition of Drug Resistance by Partial Duplication of Topoisomerase I Cancer Res., June 1, 1999; 59(11): 2701 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kaufmann, J. E. Karp, P. A. Svingen, S. Krajewski, P. J. Burke, S. D. Gore, and J. C. Reed Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse Blood, February 1, 1998; 91(3): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
